Nucleoside to treat drug-resistant HBV presented at HEP-DART

Published: 2011-12-16 06:58:00

Updated: 2011-12-16 06:58:00

Bukwang Pharmaceutical Co. announces that interim results of physician-sponsored studies of a novel antiviral compound ‘FMCA’ and its prodrugs for the treatment of chronic hepatitis B virus (HBV) was presented at the Frontiers in Drug Development in Viral Hepatitis (HEP-DART) conference being hel...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK